Troxerutin
(Synonyms: 维脑路通; Trihydroxyethylrutin) 目录号 : GC15933
A flavonoid with diverse biological activities
Cas No.:7085-55-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
The cells are plated at a density of 4×103/well in a 96-well plate. At 70 to 80% confluence, the cells are treated with Troxerutin at concentrations ranging between 0 and 60 μM for 24 h at 37°C. Subsequently, 10 μL water soluble tetrazolium salt assay solution is added to each well and, following incubation for 30 min at 37°C, the optical density is measured at 490 nm using a reader. To examine Troxerutin mediated ROS protection, the cells are pretreated with Troxerutin at the following concentrations: 0, 5, 10 and 15 μM for 8 h. Subsequently, 750 μM H2O2 is added to each well. Following incubation for 24 h at 37°C, cell viability is evaluated using an Cell Viability Assay kit. The level of cell viability (%) is normalized to that of 0.1% dimethyl-sulfoxide (DMSO)-treated cells. Each experiment is repeated at least three times[1]. |
|
Animal experiment: |
Thirty two adult male Wistar rats weighing 250 to 300 grams are used in this study. The animals are randomly divided into four groups (n=8/each) as: group I: control (C), group II: control with Troxerutin (C+TXR), group III: diabetic (D), and group IV: diabetic with Troxerutin (D+TXR). The control rats are received the same amount of citrate buffer alone. Development of diabetes is confirmed by measuring blood glucose levels, 72 hours later. Animals with blood glucose levels higher than 16.65 mM (300 mg/dL) are considered diabetic and those with blood glucose levels lower than this value are excluded from the experiment. Troxerutin (150 mg/kg/day) is administered orally, once daily for four weeks. After 10 weeks of induction of diabetes, diabetic animals as well as the time-matched controls are killed and aortic samples are collected[3]. |
|
References: [1]. Lim KM, et al. Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells. Mol Med Rep. 2015 Aug;12(2):2650-60. |
|
Troxerutin can also offer protection against DNA strand breaks and micronuclei formation induced by γ–radiation (GR), it enhances repair of DNA strand breaks induced by radiation. In lymphocytes, treatment with 1mM troxerutin significantly decreased the induction of micronuclei resulted from the exposure to 2 Gy γ-radiation by 41.26% [1].
GR can induce cellular damage and apoptosis. It can cause double-stranded and single-stranded breaks in the genomic DNA [2].
Under ex vivo condition of GR (2 Gy), DNA strand breaks were induced by the radiation. Treatment with troxerutin protected the human peripheral blood leucocytes from this GR effect. In the human lymphocytes, the micronuclei induction resulted from GR was significantly inhibited by troxerutin (1 mM) [1].
In mice, micronuclei formation in blood reticulocytes was significantly inhibited by the intraperitoneal administration of troxerutin (175 mg/kg) before and after whole body radiation exposure. 1 h prior to 4 Gy γ -radiation exposure, in bone marrow cells and blood leucocytes, the yield of DNA strand breaks was dose-dependently decreased by the administration of troxerutin at different doses (75, 125 and 175 mg/kg body weight). The dose-dependent protection was less pronounced in blood leucocytes than in bone marrow cells. In mice, 1 h prior or immediately after whole body irradiation, administration of troxerutin at 175 mg/kg body weight (i.p.) decrease the strand breaks depended on the post-irradiation interval [1].
References:
[1]. Maurya DK, Balakrishnan S, Salvi VP, et al. Protection of cellular DNA from gamma-radiation-induced damages and enhancement in DNA repair by troxerutin. Mol Cell Biochem, 2005, 280(1-2):57-68.
[2]. Chen YR, Meyer CF and Tan TH. Persistent Activation of c-Jun N-terminal Kinase 1 (JNK1) in γ Radiation-induced Apoptosis. J Biol Chem, 1996, 271(2): 631–634.
| Cas No. | 7085-55-4 | SDF | |
| 别名 | 维脑路通; Trihydroxyethylrutin | ||
| 化学名 | 2-(3,4-bis(2-hydroxyethoxy)phenyl)-5-hydroxy-7-(2-hydroxyethoxy)-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one | ||
| Canonical SMILES | C[C@@](O1)([H])[C@@](O)([H])[C@](O)([H])[C@](O)([H])[C@]1([H])OC[C@]2([H])[C@](O)([H])[C@@](O)([H])[C@](O)([H])[C@@](OC(C(C3=C(O)C=C(OCCO)C=C3O4)=O)=C4C5=CC(OCCO)=C(OCCO)C=C5)([H])O2 | ||
| 分子式 | C33H42O19 | 分子量 | 742.68 |
| 溶解度 | ≥ 74.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3465 mL | 6.7324 mL | 13.4647 mL |
| 5 mM | 0.2693 mL | 1.3465 mL | 2.6929 mL |
| 10 mM | 0.1346 mL | 0.6732 mL | 1.3465 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。